PRFX
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/S of 135.62 makes traditional valuation impossible.
- Low P/B ratio
- Extreme P/S ratio
- No Graham Number available
- Negative Forward P/E
Growth is measured from a near-zero or deeply negative base.
- Improving EPS trend (though still negative)
- No revenue growth data
- Negative earnings trajectory
Consistent and total destruction of capital over 5 years.
- 5Y Change: -99.7%
- 1Y Change: -73.4%
Liquidity is the only saving grace; operational health is non-existent.
- No debt
- Current ratio > 1.5
- Piotroski F-Score 4/9
- Negative ROE/ROA
Company is in no position to return capital.
- No dividend history
- 0/100 strength score
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PRFX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PRFX
PRF Technologies Ltd.
Primary
|
-99.7% | -98.6% | -73.4% | -56.0% | +17.2% | +3.0% |
|
IMCC
IM Cannabis Corp.
Peer
|
-99.9% | -91.4% | -72.7% | -81.3% | -57.0% | +6.5% |
|
INM
InMed Pharmaceuticals Inc.
Peer
|
-100.0% | -97.1% | -71.7% | -66.3% | -10.5% | +5.6% |
|
HCWB
HCW Biologics Inc.
Peer
|
-99.9% | -99.4% | -96.3% | -91.0% | -30.6% | +36.0% |
|
RDGT
Ridgetech, Inc.
Peer
|
-100.0% | -99.9% | -98.5% | -99.1% | -99.3% | -11.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PRFX
PRF Technologies Ltd.
|
BEARISH | $2.31M | - | -90.4% | -% | $2.73 | |
|
IMCC
IM Cannabis Corp.
|
BEARISH | $2.25M | - | -% | -20.7% | $0.36 | Compare |
|
INM
InMed Pharmaceuticals Inc.
|
BEARISH | $2.37M | - | -97.2% | -170.1% | $0.72 | Compare |
|
HCWB
HCW Biologics Inc.
|
BEARISH | $2.45M | - | -% | -% | $0.36 | Compare |
|
RDGT
Ridgetech, Inc.
|
BEARISH | $2.0M | - | -8.0% | 10.3% | $2.23 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
PRFX has identified a material weakness in its internal control over financial reporting, which may impair its ability to produce accurate financial statements or comply with regulations. The company is currently exempt from providing an independent attestation report on internal controls as a non-accelerated filer under the JOBS Act.
PRFX has identified a material weakness in its internal control over financial reporting, which may impair the company's ability to produce timely and accurate financial statements. The company is currently exempt from providing an independent attestation report on these controls due to its status as an emerging growth company under the JOBS Act.
Past News Coverage
Recent headlines mentioning PRFX from our newsroom.